Ligand Announces Positive Preclinical Data on Small Molecule Erythropoietin Receptor Agonists
Ligand Announces Presentation of Data from Multiple Studies of Dinaciclib by its Partner Merck at the ASH Annual Meeting
Ligand Reverse Stock Split Effective Today
Ligand Pharmaceuticals Announces Third Quarter Results
Ligand Announces 1-for-6 Reverse Stock Split
Ligand Announces Approval for Revolade(R) in Japan
Ligand Awarded $2 Million from U.S. Government Under the Patient Protection and Affordable Care Act
Ligand to Report Third Quarter Results on November 9
Ligand to Present at the Oppenheimer 21st Annual Healthcare Conference on November 2
Ligand Announces Market Launch of Bazedoxifene in Japan and Spain for the Treatment of Postmenopausal Osteoporosis
Ligand Appoints Sunil Patel to Board of Directors
Ligand to Divest Combinatorial Compound Library and Screening Technology for $1.8 Million
Ligand Enters into Agreement with Proximagen for CXCR4 Target
Ligand to Present at the Stifel Nicolaus Healthcare Conference on September 17
